



HHS Public Access

Author manuscript

Nat Genet. Author manuscript; available in PMC 2019 August 28.

Published in final edited form as:

Nat Genet. 2019 February ; 51(2): 245–257. doi:10.1038/s41588-018-0309-3.

* jonathan.pierre.beauchamp@gmail.com; r.karlssonlinner@vu.nl.

AUTHOR CONTRIBUTIONS:

J.P.B., P.D.K., and D.J.B. designed and oversaw the study. J.P.B. closely supervised the analyses and led the writing of the manuscript. R.K.L. was the lead analyst, responsible for quality control, the meta-analyses, summarizing the overlap across the results of the various GWAS, and the SNP heritability analyses. E.K. conducted the population stratification, replication, and proxy-phenotype analyses. R.W. led the genetic correlation analyses, and M.A.F. contributed to those analyses. P.B. led the polygenic score prediction analyses, and R.K.L., E.K., R.W., A.A., R.d.V., M.A.F., and M.G.N. contributed to those analyses. P.B. and C.L.Z. conducted the MTAG analyses. The bioinformatics analyses were led by S.F.W.M. Analysts who assisted S.F.W.M. include: J.G. and M.T. (SMR), A.R.H. (MAGMA), G.A.M. (Gene Network) and P.N.T. (DEPICT). M.L. conducted the review of the literature attempting to link risk tolerance to biological pathways. R.K.L. prepared the majority of figures; E.K. and S.P.T. also prepared some figures. A.O., C.A.R., and S.P.T. helped with several additional analyses. D.C., J.G., and J.J.L. provided helpful advice and feedback on various aspects of the study design. All authors contributed to and critically reviewed the manuscript. P.B., R.K.L., E.K., S.F.W.M., and R.W. made especially major contributions to the writing and editing.

CONTRIBUTOR LIST FOR THE 23andMe RESEARCH TEAM: Michelle Agee²⁹, Babak Alipanahi²⁹, Robert K Bell²⁹, Katarzyna Bryc²⁹, Sarah L Elson²⁹, Nicholas A Furlotte²⁹, Karen E Huber²⁹, Nadia K Litterman²⁹, Jennifer C McCreight²⁹, Matthew H McIntyre²⁹, Joanna L Mountain²⁹, Carrie A M Northover²⁹, Steven J Pitts²⁹, J Fah Sathirapongasuti²⁹, Olga V Sazonova²⁹, Janie F Shelton²⁹, Suyash Shringarpure²⁹, Chao Tian²⁹, Joyce Y Tung²⁹, Vladimir Vacic²⁹, and Catherine H Wilson²⁹

CONTRIBUTOR LIST FOR THE eQTLgen CONSORTIUM: Mawussé Agbessi⁹², Habibul Ahsan⁹³, Isabel Alves⁹², Anand Andiappan⁹⁴, Philip Awaalla⁹², Alexis Battle⁹⁵, Frank Beutner⁹⁶, Marc Jan Bonder⁹⁷, Dorret I Boomsma¹⁵, Mark Christiansen⁹⁸, Anniqe Claringbould⁹⁷, Patrick Deelen⁹⁷, Tõnu Esko⁷², Marie-Julie Fave⁹², Lude Franke⁹⁷, Timothy Fraying⁹⁹, Sina A Gharib^{100,101}, Gregory Gibson¹⁰², Bastiaan Heijmans¹⁰³, Gibran Hemani¹⁰⁴, Rick Jansen¹⁰⁵, Mika Kähönen¹⁰⁶, Anette Kalnapenkis⁷², Silva Kasela⁷², Johannes Kettunen¹⁰⁷, Yungil Kim^{95,108}, Holger Kirsten¹⁰⁹, Peter Kovacs¹¹⁰, Knut Krohn¹¹¹, Jaanika Kronberg-Guzman⁷², Viktorija Kukushkina⁷², Zoltan Kutalik¹¹², Bernett Lee⁹⁴, Terho Lehtimäki¹¹³, Markus Loeffler¹⁰⁹, Urko M Marigorta¹⁰², Andres Metspalu⁷², Lili Milani⁷², Grant W Montgomery²⁰, Martina Müller-Nurasyid¹¹⁴, Matthias Nauck¹¹⁵, Michel G Nivard¹⁰⁵, Brenda Penninx¹⁰⁵, Markus Perola¹¹⁶, Natalia Pervjakova⁷², Brandon Pierce⁹³, Joseph Powell¹¹⁷, Holger Prokisch¹¹⁸, Bruce M Psaty⁹⁸, Olli Raitakari¹¹⁹, Susan Ring^{104,120}, Samuli Ripatti¹⁰⁷, Olaf Rotzchke⁹⁴, Sina Rüeger¹¹², Ashis Saha⁹⁵, Markus Scholz¹⁰⁹, Katharina Schramm¹¹⁴, Ilkka Seppälä¹¹³, Michael Stumvoll¹²¹, Patrick Sullivan⁵⁵, Peter-Bram t Hoen¹²², Alexander Teumer¹²³, Joachim Thiery¹²⁴, Lin Tong⁹³, Anke Tönjes¹²¹, Jenny van Dongen¹⁰⁵, Joyce van Meurs⁶⁶, Joost Verloouw⁶⁶, Peter M Visscher²⁰, Uwe Völker¹²⁵, Urmo Vösa⁹⁷, Harm-Jan Westra⁹⁷, Hanieh Yaghootkar⁹⁹, Jian Yang^{20,69}, Biao Zeng¹⁰², and Futao Zhang²⁰

CONTRIBUTOR LIST FOR THE SOCIAL SCIENCE GENETIC ASSOCIATION CONSORTIUM: Aysu Okbay^{1,3}, Jonathan P Beauchamp¹⁴, Mark Alan Fontana^{10,11}, James J Lee⁸⁵, Tune H Pers^{18,19}, Cornelius A Rietveld^{2,16,17}, Patrick Turley^{6,8,80}, Guo-Bo Chen⁶⁹, Valur Emilsson^{126,127}, S Fleur W Meddens^{1,2,3}, Sven Oskarsson¹²⁸, Joseph K Pickrell¹²⁹, Kevin Thom⁸⁶, Pascal Timshel^{18,19}, Ronald de Vlaming^{1,2,3}, Abdel Abdellou¹⁵, Tarunveer S Ahluwalia^{18,130,131}, Jonas Bacelis¹³², Clemens Baumbach^{133,134}, Gyda Björnsdóttir¹³⁵, Johannes H Brandsma¹³⁶, Maria Pina Concas¹³⁷, Jaime Derringer¹³⁸, Nicholas A Furlotte²⁹, Tessel E Galesloot¹²², Giorgia Grotto¹³⁹, Richa Gupta¹⁴⁰, Leanne M Hall^{141,142}, Sarah E Harris^{143,144}, Edith Hofer^{145,146}, Momoko Horikoshi^{147,148}, Jennifer E Huffman⁸³, Kadri Kaasik¹⁴⁹, Ioanna P Kalafati¹⁵⁰, Robert Karlsson⁵⁵, Augustine Kong¹³⁵, Jari Lahti^{149,151}, Sven J van der Lee¹⁷, Christiaan de Leeuw^{1,152}, Penelope A Lind¹⁵³, Karl-Oskar Lindgren¹²⁸, Tian Liu⁸², Massimo Mangino^{154,155}, Jonathan Marten⁸³, Evelin Mihailov⁷², Michael B Miller⁸⁵, Peter J van der Most¹⁵⁶, Christopher Oldmeadow^{157,158}, Antony Payton^{159,160}, Natalia Pervjakova⁷², Wouter J Peyrot¹⁶¹, Yong Qian¹⁶², Olli Raitakari¹¹⁹, Rico Rueedi^{163,164}, Erika Salvi¹⁶⁵, Börge Schmidt¹⁶⁶, Katharina E Schraut³³, Jianxin Shi¹⁶⁷, Albert V Smith^{126,168}, Raymond A Poot¹³⁶, Beate St Pourcain^{104,169}, Alexander Teumer¹²³, Gudmar Thorleifsson¹³⁵, Niek Verweij¹⁷⁰, Dragana Vuckovic¹³⁹, Juergen Wellmann¹⁷¹, Harm-Jan Westra⁹⁷, Jingyun Yang^{172,173}, Wei Zhao¹⁷⁴, Zhihong Zhu⁶⁹, Behrooz Z Alizadeh^{156,175}, Najaf Amin¹⁷, Andrew Bakshi⁶⁹, Sebastian E Baumeister^{123,176}, Ginevra Biino¹⁷⁷, Klaus Bonnelykke¹³⁰, Patricia A Boyle^{172,178}, Harry Campbell³³, Francesco P Cappucco¹⁷⁹, Gail Davies^{143,180}, Jan-Emmanuel De Neve¹⁸¹, Panos Deloukas^{182,183}, Ilja Demuth^{184,185}, Jun Ding¹⁶², Peter Eibich^{26,27,28}, Lewin Eisele¹⁶⁶, Niina Eklund¹¹⁶, David M Evans^{104,186}, Jessica D Faul¹⁸⁷, Mary F Feitosa¹⁸⁸, Andreas J Forstner^{189,190}, Ilaria Gandin¹³⁹, Bjarni Gunnarsson¹³⁷, Bjarni H Halldórsson^{135,191}, Tamara B Harris¹⁹², Andrew C Heath¹⁹³, Lynne J Hocking¹⁹⁴, Elizabeth G Holliday^{157,158}, Georg Homuth¹²⁵, Michael A Horan¹⁹⁵, Jouke-Jan Hottenga¹⁵, Philip L de Jager^{196,197,198}, Peter K Joshi³³, Astanad Jugessur¹⁹⁹, Marika A Kaakinen²⁰⁰, Mika Kähönen¹⁰⁶, Stavroula Kanoni¹⁸², Liisa Keltigangas-Järvinen¹⁴⁹, Lambertus A L M Kiemeny¹²², Ivana Kolcic²⁰¹, Seppo Koskinen¹¹⁶, Aldi T Kraja¹⁸⁸, Martin Kroh²⁷, Zoltan Kutalik¹¹², Antti Latvala¹⁴⁰, Lenore J Launer²⁰², Mael P Lebreton^{12,13}, Douglas F Levinson²⁰³, Paul Lichtenstein⁵⁵, Peter Lichtner²⁰⁴, David C M Liewald^{143,180}, Anu Loukola¹⁴⁰, Pamela A Madden¹⁹³, Reedik Mägi⁷², Tomi Mäki-Opas¹¹⁶, Riccardo E Marioni^{69,143,205}, Pedro Marques-Vidal²⁰⁶, Gerardus A Meddens³⁷, George McMahon¹⁰⁴, Christa Meisinger¹³⁴, Thomas Meitinger¹¹⁸, Yusplriti Milaneschi¹⁶¹, Lili Milani⁷², Grant W Montgomery²⁰, Ronny Myhre¹⁹⁹, Christopher P Nelson^{141,142}, Dale R Nyholt^{207,208}, William E R Ollie¹⁵⁹, Aarno Palotie^{6,25,196,209,210,211}, Lavinia Paternoster¹⁰⁴, Nancy L Pedersen⁵⁵, Katja E Petrovic¹⁴⁵, David J Porteous¹⁴⁴, Katri Räikkönen^{149,151}, Susan M Ring¹⁰⁴, Antonietta Robino²¹², Olga Rostapshova^{5,213}, Igor Rudan³³, Aldo Rustichini²¹⁴, Veikko Salomaa¹¹⁶, Alan R Sanders^{68,215}, Antti-Pekka Sarin^{210,216}, Helena Schmidt^{145,217}, Rodney J Scott^{158,218}, Blair H Smith²¹⁹, Jennifer A Smith¹⁷⁴, Jan A Staessen^{220,221}, Elisabeth Steinhagen-Thiessen¹⁸⁴, Konstantin Strauch^{114,222}, Antonio Terracciano²²³, Martin D Tobin²²⁴, Sheila Ulivi²¹², Simona Vaccargiu¹³⁷, Lydia Quayle¹⁵⁴, Frank J van Rooij¹⁷, Cristina Venturini^{154,155}, Anna A E Vinkhuyzen⁶⁹, Uwe Völker¹²⁵, Henry Völzke¹²³, Judith M Vonk¹⁵⁶, Diego Vozzi²¹³, Johannes Waage^{130,131}, Erin B Ware^{174,225}, Gonneke Willemsen¹⁵, John R Attia^{157,158}, David A Bennett^{172,173}, Klaus Berger¹⁷⁰, Lars Bertram^{36,70,71}, Hans Bisgaard¹³⁰, Dorret I Boomsma¹⁵, Ingrid B Borecki¹⁸⁸, Ute Bültmann²²⁶, Christopher F Chabris²²⁷, Francesco Cucca²²⁸, Daniele Cusi^{165,229}, Ian J Deary^{143,180}, George V Dedoussis¹⁵⁰, Cornelia M van Duijn¹⁷, Johan G Eriksson^{151,230}, Barbara Franke²³¹, Lude Franke⁹⁷, Paolo Gasparini^{139,212,232}, Pablo V Gejman^{68,215}, Christian Gieger¹³³, Hans-Jürgen Grabe^{233,234}, Jacob Gratten^{20,84}, Patrick J F Groenen^{2,50}, Vilundur Gudnason^{126,168}, Pim van der

Genome-wide association analyses of risk tolerance and risky

Harst^{97,170,235}, Caroline Hayward^{83,236}, David A Hinds²⁹, Wolfgang Hoffmann¹²³, Elina Hyppönen^{237,238,239}, William G Iacono⁸⁵, Bo Jacobsson^{132,199}, Marjo-Riitta Järvelin^{240,241,242,243}, Karl-Heinz Jöckel¹⁶⁶, Jaakko Kaprio^{140,116,210}, Sharon L R Kardia¹⁷⁴, Terho Lehtimäki¹¹³, Steven F Lehrer^{244,245}, Patrik K E Magnusson⁵⁵, Nicholas G Martin²⁴⁶, Matt McGue⁸⁵, Andres Metspalu⁷², Neil Pendleton^{247,248}, Brenda Penninx¹⁰⁵, Markus Perola¹¹⁶, Nicola Pirastu¹³⁹, Mario Pirastu¹³⁷, Ozren Polasek^{33,249}, Danielle Posthuma^{1,78}, Christine Power²³⁹, Michael A Province¹⁸⁸, Nilesh J Samani^{141,142}, David Schlessinger¹⁶², Reinhold Schmidt¹⁴⁵, Thorkild I A Sørensen^{18,104,250}, Tim D Spector¹⁵⁴, Kari Stefansson^{135,168}, Unnur Thorsteinsdóttir^{135,168}, A Roy Thurik^{2,65}, Nicholas J Timpson¹⁰⁴, Henning Tiemeier¹⁷, Joyce Y Tung²⁹, André G Uitterlinden⁶⁶, Veronique Vitart⁸³, Peter Vollenweider²⁰⁵, David R Weir¹⁸⁷, James F Wilson^{33,83}, Alan F Wright⁸³, Dalton C Conley^{251,252}, Robert F Krueger⁸⁵, George Davey Smith¹⁰⁴, Albert Hofman^{7,17}, David I Laibson⁵, Sarah E Medland¹⁵³, Michelle N Meyer⁷⁴, Jian Yang^{20,69}, Magnus Johannesson⁷³, Peter M Visscher²⁰, Tõnu Esko⁷², Philipp D Koellinger^{1,3,89}, David Cesarini⁸⁶, and Daniel J Benjamin^{80,87,88}

⁹² Computational Biology, Ontario Institute for Cancer Research, Toronto, Canada
⁹³ Department of Public Health Sciences, University of Chicago, Chicago, USA
⁹⁴ Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore
⁹⁵ Department of Computer Science, Johns Hopkins University, Baltimore, USA
⁹⁶ Heart Center Leipzig, Universität Leipzig, Leipzig, Germany
⁹⁷ Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, 9700 RB, The Netherlands
⁹⁸ Cardiovascular Health Research Unit, Departments of Epidemiology, Medicine, and Health Services, University of Washington, Seattle, USA
⁹⁹ Exeter Medical School, University of Exeter, Exeter, UK
¹⁰⁰ Department of Medicine, University of Washington, Seattle, USA
¹⁰¹ Kaiser Permanente Washington Health Research Institute, Seattle, USA
¹⁰² School of Biological Sciences, Georgia Tech, Atlanta, USA
¹⁰³ Leiden University Medical Centre, Leiden, The Netherlands
¹⁰⁴ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
¹⁰⁵ Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
¹⁰⁶ Department of Clinical Physiology, Tampere University Hospital and Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
¹⁰⁷ University of Helsinki, Helsinki, Finland
¹⁰⁸ Genetics and Genomic Science Department, Icahn School of Medicine at Mount Sinai, New York, USA
¹⁰⁹ Institut für Medizinische Informatik, Statistik und Epidemiologie, LIFE – Leipzig Research Center for Civilization Diseases, Universität Leipzig, Leipzig, Germany
¹¹⁰ IFB Adiposity Diseases, Universität Leipzig, Leipzig, Germany
¹¹¹ Interdisciplinary Center for Clinical Research, Faculty of Medicine, Universität Leipzig, Leipzig, Germany
¹¹² Lausanne University Hospital, Lausanne, Switzerland
¹¹³ Department of Clinical Chemistry, Fimlab Laboratories and Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
¹¹⁴ Institute of Genetic Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany
¹¹⁵ Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany
¹¹⁶ National Institute for Health and Welfare, University of Helsinki, Helsinki, Finland
¹¹⁷ Garvan Institute of Medical Research, Garvan-Weizmann Centre for Cellular Genomics, Sydney, Australia
¹¹⁸ Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany
¹¹⁹ Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital and University of Turku, Turku, Finland
¹²⁰ Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
¹²¹ Department of Medicine, Universität Leipzig, Leipzig, Germany
¹²² Radboud University Medical Center, Radboud University, Nijmegen, The Netherlands
¹²³ Institute for Community Medicine, University Medicine Greifswald, Greifswald 17475, Germany
¹²⁴ Institute for Laboratory Medicine, LIFE – Leipzig Research Center for Civilization Diseases, Universität Leipzig, Leipzig, Germany
¹²⁵ Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany
¹²⁶ Icelandic Heart Association, Kopavogur 201, Iceland
¹²⁷ Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavík 107, Iceland
¹²⁸ Department of Government, Uppsala University, Uppsala 751 20, Sweden
¹²⁹ New York Genome Center, New York, New York 10013, USA
¹³⁰ COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen 2820, Denmark
¹³¹ Steno Diabetes Center, Gentofte 2820, Denmark
¹³² Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg 416 85, Sweden
¹³³ Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany

behaviors in over one million individuals identify hundreds of

- 134 Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany
- 135 deCODE Genetics/Amgen Inc., Reykjavik 101, Iceland
- 136 Department of Cell Biology, Erasmus Medical Center, Rotterdam, 3015 CN, The Netherlands
- 137 Istituto di Ricerca Genetica e Biomedica U.O.S. di Sassari, National Research Council of Italy, Sassari 07100, Italy
- 138 Psychology, University of Illinois, Champaign, Illinois 61820, USA
- 139 Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste 34100, Italy
- 140 Department of Public Health, University of Helsinki, 00014 Helsinki, Finland
- 141 Department of Cardiovascular Sciences, University of Leicester, Leicester LE3 9QP, UK
- 142 NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester LE3 9QP, UK
- 143 Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh EH8 9JZ, UK
- 144 Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK
- 145 Department of Neurology, General Hospital and Medical University Graz, Graz 8036, Austria
- 146 Institute for Medical Informatics, Statistics and Documentation, General Hospital and Medical University Graz, Graz 8036, Austria
- 147 Oxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford OX3 7LE, UK
- 148 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
- 149 Institute of Behavioural Sciences, University of Helsinki, 00014 Helsinki, Finland
- 150 Nutrition and Dietetics, Health Science and Education, Harokopio University, Athens 17671, Greece
- 151 Folkhälsan Research Centre, 00014 Helsingfors, Finland
- 152 Institute for Computing and Information Sciences, Radboud University Nijmegen, Nijmegen, 6525 EC, The Netherlands
- 153 Quantitative Genetics, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia
- 154 Department of Twin Research and Genetic Epidemiology, King's College London, London SE1 7EH, UK
- 155 NIHR Biomedical Research Centre, Guy's and St. Thomas' Foundation Trust, London SE1 7EH, UK
- 156 Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, 9700 RB, The Netherlands
- 157 Public Health Stream, Hunter Medical Research Institute, New Lambton, NSW 2305, Australia
- 158 Faculty of Health and Medicine, University of Newcastle, Newcastle, NSW 2300, Australia
- 159 Centre for Integrated Genomic Medical Research, Institute of Population Health, The University of Manchester, Manchester M13 9PT, UK
- 160 Human Communication and Deafness, School of Psychological Sciences, The University of Manchester, Manchester M13 9PL, UK
- 161 Psychiatry, VU University Medical Center & GGZ inGeest, Amsterdam, 1081 HL, The Netherlands
- 162 Laboratory of Genetics, National Institute on Aging, Baltimore, Maryland 21224, USA
- 163 Department of Medical Genetics, University of Lausanne, Lausanne 1005, Switzerland
- 164 Swiss Institute of Bioinformatics, Lausanne 1015, Switzerland
- 165 Department Of Health Sciences, University of Milan, Milano 20142, Italy
- 166 Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, Essen 45147, Germany
- 167 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892-9780, USA
- 168 Faculty of Medicine, University of Iceland, Reykjavik 101, Iceland
- 169 School of Oral and Dental Sciences, University of Bristol, Bristol BS1 2LY, UK
- 170 Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, 9700 RB, The Netherlands
- 171 Institute of Epidemiology and Social Medicine, University of Münster, Münster 48149, Germany
- 172 Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois 60612, USA
- 173 Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
- 174 Department of Epidemiology, University of Michigan, Ann Arbor, Michigan 48109, USA
- 175 Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, 9713 GZ, The Netherlands
- 176 Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg D-93053, Germany
- 177 Institute of Molecular Genetics, National Research Council of Italy, Pavia 27100, Italy
- 178 Department of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
- 179 Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
- 180 Department of Psychology, University of Edinburgh, Edinburgh EH8 9JZ, UK
- 181 Saïd Business School, University of Oxford, Oxford OX1 1HP, UK
- 182 William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
- 183 Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-HD), King Abdulaziz University, Jeddah 21589, Saudi Arabia
- 184 The Berlin Aging Study II; Research Group on Geriatrics, Charité – Universitätsmedizin Berlin, Germany, Berlin 13347, Germany
- 185 Institute of Medical and Human Genetics, Charité-Universitätsmedizin, Berlin, Berlin 13353, Germany
- 186 The University of Queensland Diamantina Institute, The Translational Research Institute, Brisbane, QLD 4102, Australia

loci and shared genetic influences

- 187 Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, Michigan 48109, USA
 188 Department of Genetics, Division of Statistical Genomics, Washington University School of Medicine, St. Louis, Missouri 63018, USA
 189 Institute of Human Genetics, University of Bonn, Bonn 53127, Germany
 190 Department of Genomics, Life and Brain Center, University of Bonn, Bonn 53127, Germany
 191 Institute of Biomedical and Neural Engineering, School of Science and Engineering, Reykjavik University, Reykjavik 101, Iceland
 192 Laboratory of Epidemiology, Demography, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892-9205, USA
 193 Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, USA
 194 Division of Applied Health Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK
 195 Manchester Medical School, The University of Manchester, Manchester M13 9PT, UK
 196 Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA
 197 Program in Translational NeuroPsychiatric Genomics, Departments of Neurology & Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
 198 Harvard Medical School, Boston, Massachusetts 02115, USA
 199 Department of Genes and Environment, Norwegian Institute of Public Health, N-0403 Oslo, Norway
 200 Department of Genomics of Common Disease, Imperial College London, London, W12 0NN, UK
 201 Public Health, Medical School, University of Split, 21000 Split, Croatia
 202 Neuroepidemiology Section, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892-9205, USA
 203 Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California 94305-5797, USA
 204 Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK
 205 Department of Internal Medicine, Internal Medicine, Lausanne University Hospital (CHUV), Lausanne 1011, Switzerland
 206 Tema BV, Hoofddorp, 2131 HE, The Netherlands
 207 Molecular Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia
 208 Institute of Health and Biomedical Innovation, Queensland Institute of Technology, Brisbane, QLD 4059, Australia
 209 Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
 210 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki 00014, Finland
 211 Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
 212 Medical Genetics, Institute for Maternal and Child Health IRCCS "Burlo Garofolo", Trieste 34100, Italy
 213 Social Impact, Arlington, Virginia 22201, USA
 214 Department of Economics, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
 215 Department of Psychiatry and Behavioral Sciences, NorthShore University HealthSystem, Evanston, Illinois 60201-3137, USA
 216 Public Health Genomics Unit, National Institute for Health and Welfare, 00300 Helsinki, Finland
 217 Research Unit for Genetic Epidemiology, Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, General Hospital and Medical University, Graz, Graz 8010, Austria
 218 Information Based Medicine Stream, Hunter Medical Research Institute, New Lambton, NSW 2305, Australia
 219 Medical Research Institute, University of Dundee, Dundee DD1 9SY, UK
 220 Research Unit Hypertension and Cardiovascular Epidemiology, Department of Cardiovascular Science, University of Leuven, Leuven 3000, Belgium
 221 R&D VitaK Group, Maastricht University, Maastricht, 6229 EV, The Netherlands
 222 Institute of Medical Informatics, Biometry and Epidemiology, Chair of Genetic Epidemiology, Ludwig Maximilians-Universität, Munich 81377, Germany
 223 Department of Geriatrics, Florida State University College of Medicine, Tallahassee, Florida 32306, USA
 224 Department of Health Sciences and Genetics, University of Leicester, Leicester LE1 7RH, UK
 225 Research Center for Group Dynamics, Institute for Social Research, University of Michigan, Ann Arbor, Michigan 48104, USA
 226 Department of Health Sciences, Community & Occupational Medicine, University of Groningen, University Medical Center Groningen, Groningen, 9713 AV, The Netherlands
 227 Department of Psychiatry, Union College, Schenectady, New York 12308, USA
 228 Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche, c/o Cittadella Universitaria di Monserrato, Monserrato, Cagliari 9042, Italy
 229 Institute of Biomedical Technologies, Italian National Research Council, Segrate (Milano) 20090, Italy
 230 Department of General Practice and Primary Health Care, University of Helsinki, 00014 Helsinki, Finland
 231 Departments of Human Genetics and Psychiatry, Donders Centre for Neuroscience, Nijmegen, 6500 HB, The Netherlands
 232 Sidra, Experimental Genetics Division, Sidra, Doha 26999, Qatar
 233 Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald 17475, Germany
 234 Department of Psychiatry and Psychotherapy, HELIOS-Hospital Stralsund, Stralsund 18437, Germany
 235 Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, 1105 AZ, The Netherlands
 236 Generation Scotland, Centre for Genomics and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK
 237 Centre for Population Health Research, School of Health Sciences and Sansom Institute, University of South Australia, Adelaide, SA 5000, Australia

A full list of authors and affiliations appears at the end of the article.

Abstract

Humans vary substantially in their willingness to take risks. In a combined sample of over one million individuals, we conducted genome-wide association studies (GWAS) of general risk tolerance, adventurousness, and risky behaviors in the driving, drinking, smoking, and sexual domains. Across all GWAS we identified hundreds of associated loci, including 99 loci associated with general risk tolerance. We report evidence of substantial shared genetic influences across risk tolerance and the risky behaviors: 46 of the 99 general risk tolerance loci contain a lead SNP for at least one of our other GWAS, and general risk tolerance is genetically correlated ($|\hat{r}_g| \sim 0.25$ to 0.50) with a range of risky behaviors. Bioinformatics analyses imply that genes near general-risk-tolerance-associated SNPs are highly expressed in brain tissues and point to a role for glutamatergic and GABAergic neurotransmission. We found no evidence of enrichment for genes previously hypothesized to relate to risk tolerance.

INTRODUCTION:

Choices in important domains of life, including health, fertility, finance, employment, and social relationships, rarely have consequences that can be anticipated perfectly. The degree of variability in possible outcomes is called risk. Risk tolerance—defined as the willingness to take risks, typically to obtain some reward—varies substantially across humans and has been actively studied in the behavioral and social sciences. An individual’s risk tolerance may vary across domains, but survey-based measures of *general* risk tolerance (e.g., “Would you describe yourself as someone who takes risks?”) have been found to be good all-around predictors of risky behaviors such as portfolio allocation, occupational choice, smoking, drinking alcohol, and starting one’s own business^{1–3}.

Twin studies have established that various measures of risk tolerance are moderately heritable ($h^2 \sim 30\%$, although estimates in the literature vary^{3–5}). Discovery of specific genetic variants associated with general risk tolerance could provide insights into underlying biological pathways; advance our understanding of how genetic influences are amplified and dampened by environmental factors; enable the construction of polygenic scores (indexes of

²³⁸ South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia

²³⁹ Population, Policy and Practice, UCL Institute of Child Health, London WC1N 1EH, UK

²⁴⁰ Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment & Health, School of Public Health, Imperial College London, London W2 1PG, UK

²⁴¹ Center for Life Course Epidemiology, Faculty of Medicine, University of Oulu, 90014 Oulu, Finland

²⁴² Unit of Primary Care, Oulu University Hospital, 90029 Oulu, Finland

²⁴³ Biocenter Oulu, University of Oulu, 90014 Oulu, Finland

²⁴⁴ Economics, NYU Shanghai, 200122 Pudong, China

²⁴⁵ Policy Studies, Queen’s University, Kingston, Ontario K7L 3N6, Canada

²⁴⁶ Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia

²⁴⁷ Centre for Clinical and Cognitive Neuroscience, Institute Brain Behaviour and Mental Health, Salford Royal Hospital, Manchester M6 8HD, UK

²⁴⁸ Manchester Institute for Collaborative Research in Ageing, University of Manchester, Manchester M13 9PL, UK

²⁴⁹ Faculty of Medicine, University of Split, Split 21000, Croatia

²⁵⁰ Institute of Preventive Medicine, Bispebjerg and Frederiksberg Hospitals, The Capital Region, Frederiksberg 2000, Denmark

²⁵¹ Department of Sociology, New York University, New York, New York 10012, USA

²⁵² School of Medicine, New York University, New York, New York 10016, USA

many genetic variants) that can be used as overall measures of genetic influences on individuals; and help distinguish genetic variation associated with general versus domain-specific risk tolerance.

Although risk tolerance has been one of the most studied phenotypes in social science genetics, most claims of positive findings have been based on small-sample candidate gene studies (Supplementary Table 1), whose limitations are now appreciated⁶. To date, only two loci associated with risk tolerance have been identified in genome-wide association studies (GWAS)^{7,8}.

Here, we report results from large-scale GWAS of self-reported general risk tolerance (our primary phenotype) and six supplementary phenotypes: “adventurousness” (defined as the self-reported tendency to be adventurous vs. cautious); four risky behaviors: “automobile speeding propensity” (the tendency to drive faster than the speed limit), “drinks per week” (the average number of alcoholic drinks consumed per week), “ever smoker” (whether one has ever been a smoker), and “number of sexual partners” (the lifetime number of sexual partners); and the first principal component (PC) of these four risky behaviors, which we interpret as capturing the general tendency to take risks across domains. All seven phenotypes are coded such that higher phenotype values are associated with higher risk tolerance or risk taking. Table 1 lists, for each GWAS, the datasets we analyzed and the GWAS sample sizes.

RESULTS:

Association analyses

All seven GWAS were performed in European-ancestry subjects; included controls for the top 10 (or more) principal components of the genetic relatedness matrix and for sex and birth year (Supplementary Table 2); and followed procedures described in a pre-specified analysis plan (see URLs) and in the Supplementary Note.

In the discovery phase of our GWAS of general risk tolerance ($n = 939,908$), we conducted a GWAS using the UK Biobank (UKB, $n = 431,126$) and then performed a sample-size-weighted meta-analysis of those results with GWAS results from a sample of research participants from 23andMe ($n = 508,782$). The UKB measure of general risk tolerance is based on the question: “Would you describe yourself as someone who takes risks? Yes / No.” The 23andMe measure is based on a question about overall comfort taking risks, with five response options ranging from “very comfortable” to “very uncomfortable.” The genetic correlation⁹ between the UKB and 23andMe cohorts ($\hat{r}_g = 0.77$, $SE = 0.02$) is smaller than one but high enough to justify our approach of pooling the two cohorts (see Section 2 in the Supplementary Note of ref.¹⁰ for a theoretical demonstration of the merits of pooling cohorts despite moderate heterogeneity of phenotype measures).

The Q-Q plot (Supplementary Fig. 1a) from the discovery GWAS exhibits substantial inflation ($\lambda_{GC} = 1.41$). According to the estimated intercept from a linkage disequilibrium (LD) Score regression¹¹, only a small share of this inflation (~5%) in test statistics is due to confounding biases such as cryptic relatedness and population stratification. To account for

these biases, we inflated GWAS standard errors by the square root of the LD Score regression intercept¹².

We identified 124 approximately independent SNPs (pairwise $r^2 < 0.1$) that attained genome-wide significance ($P < 5 \times 10^{-8}$). These 124 “lead SNPs” are listed in Supplementary Table 3 and shown in Fig. 1a. All have coefficients of determination (R^2 s) below 0.02%, and the SNP with the largest per-allele effect is estimated to increase general risk tolerance by ~ 0.026 standard deviations in our discovery sample (Supplementary Fig. 2). To test if the lead SNPs’ effect sizes are heterogeneous across the 23andMe and UKB cohorts, we generated an omnibus test statistic by summing Cochran’s Q statistics across all lead SNPs; consistent with our genetic correlation estimate of less than unity between the two cohorts, we rejected the null hypothesis of homogeneity ($P = 4.32 \times 10^{-5}$; Supplementary Note). To define genomic loci around the lead SNPs, we took the physical regions containing all SNPs in LD (pairwise $r^2 > 0.6$) with the lead SNPs and merged loci within 250 kb of each other; the 124 lead SNPs are located in 99 such loci (Supplementary Table 3). We supplemented those analyses with a conditional and joint multiple-SNP (COJO) analysis¹³, which identified 91 genome-wide significant “conditional associations” (Supplementary Table 3).

In the replication phase of our GWAS of general risk tolerance (combined $n = 35,445$), we meta-analyzed summary statistics from ten smaller cohorts. Additional details on cohort-level phenotype measures are provided in Supplementary Table 4. The cohorts’ survey questions differ in terms of their exact wording and number of response categories, but all questions ask subjects about their overall or general attitudes toward risk. The genetic correlation⁹ between the discovery and replication GWAS is 0.83 ($SE = 0.13$). 123 of the 124 lead SNPs were available or well proxied by an available SNP in the replication GWAS results. Out of these 123 SNPs, 94 have a concordant sign ($P = 1.7 \times 10^{-9}$) and 23 are significant at the 5% level in one-tailed t tests ($P = 4.5 \times 10^{-8}$) (Supplementary Fig. 3). This empirical replication record closely matches theoretical projections that take into account sampling variation and the winner’s curse (Supplementary Note).

In the UKB we tested and confirmed that a much higher fraction of males (34%) than females (19%) described themselves as risk tolerant on the general risk tolerance measure (t -test $P < 1 \times 10^{-100}$; Supplementary Fig. 4), consistent with much prior research^{14,15}. We used bivariate LD Score regression¹² to calculate the genetic correlation between GWAS performed separately in the sample of females and in the sample of males in the UKB. Our estimate ($\hat{r}_g = 0.822$, $SE = 0.033$) is high enough to justify our approach of pooling males and females in our other analyses to maximize statistical power¹⁰. Nonetheless, our estimate is significantly smaller than unity, suggesting that the autosomal genetic factors contributing to general risk tolerance, while largely similar across sexes, are not identical.

Our six supplementary GWAS—of adventurousness, the four risky behaviors, and their principal component ($n = 315,894$ to $557,923$; Supplementary Tables 4–5)—were conducted using methods comparable to those in the primary GWAS, except that they had no replication phases and most involved a single large cohort. Supplementary Fig. 1 shows Q-Q plots and Supplementary Fig. 5 shows Manhattan plots.

Table 1 provides a summary overview of the seven GWAS. We identified a total of 864 “lead associations”: the sum total of the 124 general-risk-tolerance lead SNPs together with the 740 lead SNPs from the six supplementary GWAS. (These 864 lead associations were obtained by considering each of our seven phenotypes separately and using the standard genome-wide significance P value threshold of 5×10^{-8} . If we instead consider the seven GWAS jointly and use a Bonferroni-corrected P value threshold of 7.1×10^{-9} ($= 5 \times 10^{-8}/7$), we obtain 566 lead associations across the seven GWAS.) Since we did not have the data to conduct replication analyses of the lead associations from the supplementary GWAS, we calculated the “maxFDR”¹⁶, a theoretical upper bound on the false discovery rate (FDR), for each GWAS. The maxFDR estimates were low across all GWAS (the highest estimate was 1.22×10^{-3} , for automobile speeding propensity), thus providing reassurance about the robustness of the lead associations.

Applying our locus definition, we identified a total of 703 “locus associations”: the sum total of the 99 general-risk-tolerance loci together with the 604 loci from the supplementary GWAS (Supplementary Note). Pooling the loci corresponding to the 703 locus associations, and merging loci within 250 kb from each other, yields 444 distinct loci. COJO analyses¹³ identified a sum total of 655 conditional associations across all seven GWAS. (If we instead consider the seven GWAS jointly and use a Bonferroni-corrected P value threshold of 7.1×10^{-9} ($= 5 \times 10^{-8}/7$), we obtain 464 locus associations and 505 conditional associations across the seven GWAS.) We verified that the results of the COJO analyses are consistent with those from multiple regressions using individual-level genotype-dosage data from the UKB (Supplementary Note). Supplementary Tables 3 and 6–7 report the lead SNPs, the genomic loci, and the results of the COJO analyses. Table 1 also shows the SNP heritabilities¹⁷ of the seven phenotypes, calculated from the GWAS results; the SNP heritabilities range from ~ 0.05 (for general risk tolerance) to ~ 0.16 (for the first PC of the four risky behaviors).

We note that 212 of the 864 lead associations are located within long-range LD regions¹⁸ or candidate inversions (i.e., genomic regions that are highly prone to inversion polymorphisms; Supplementary Note). Of these, only 109 are also conditional associations, and 46 are in loci that contain no conditional associations, thus indicating that many lead associations in the long-range LD regions or candidate inversions may tag causal variants that are also tagged by other lead associations. We discuss some of these regions in the next section.

Genetic overlap

There is substantial overlap across the results of our GWAS. For example, 46 of the 99 general-risk-tolerance loci contain a lead SNP of at least one of the other GWAS, and 72 of the 124 general-risk-tolerance lead SNPs are in weak LD (pairwise $r^2 > 0.1$) with a lead SNP of at least one of the other GWAS (including 45 for adventurousness and 49 for at least one of the four risky behaviors or their first PC). To empirically assess if this overlap could be attributed to chance, we conducted resampling exercises under the null hypothesis that the lead SNPs of our supplementary GWAS are distributed independently of the general-risk-

tolerance loci and lead SNPs. We strongly rejected this null hypothesis ($P < 0.0001$; Supplementary Note).

Several long-range LD regions, candidate inversions, and LD blocks¹⁹ stand out for being associated both with general risk tolerance and with all or most of the supplementary phenotypes. We tested whether the signs of the lead SNPs located in these regions tend to be concordant across our primary and supplementary GWAS. We strongly rejected the null hypothesis of no concordance ($P < 3 \times 10^{-30}$; Supplementary Note), suggesting that these regions represent shared genetic influences, rather than colocalization of causal SNPs. Fig. 1b and Supplementary Fig. 6 show local Manhattan plots for some of these long-range LD regions and candidate inversions. The long-range LD region¹⁸ on chromosome 3 (~83.4 to 86.9 Mb) contains lead SNPs from all seven GWAS as well as the most significant lead SNP from the general-risk-tolerance GWAS, rs993137 ($P = 2.14 \times 10^{-40}$), which is located in the gene *CADM2*. Another long-range LD region, on chromosome 6 (~25.3 to 33.4 Mb), covers the HLA-complex and contains lead SNPs from all GWAS except drinks per week. Three candidate inversions on chromosomes 7 (~124.6 to 132.7 Mb), 8 (~7.89 to 11.8 Mb), and 18 (~49.1 to 55.5 Mb) contain lead SNPs from six, five, and all seven of our GWAS, respectively. Finally, four other LD blocks¹⁹ that do not overlap known long-range LD or candidate inversion regions each contain lead SNPs from five of our GWAS (including general risk tolerance). While many of the lead SNPs in these regions are not conditional associations, the above results regarding the numbers of GWAS with lead SNPs in these regions also hold if we only consider the conditional associations instead of the lead SNPs in those regions. The two long-range LD regions and the three candidate inversions have previously been found to be associated with numerous phenotypes, including many cognitive and neuropsychiatric phenotypes²⁰.

To investigate genetic overlap at the genome-wide level, we estimated genetic correlations with self-reported general risk tolerance using bivariate LD Score regression⁹. (For this and all subsequent analyses involving general risk tolerance, we used the summary statistics from the combined meta-analysis of our discovery and replication GWAS.) The estimated genetic correlations with our six supplementary phenotypes are all positive, larger than ~0.25, and highly significant ($P < 2.3 \times 10^{-30}$; Fig. 2), indicating that SNPs associated with higher general risk tolerance also tend to be associated with riskier behavior. The largest estimated genetic correlations are with adventurousness ($\hat{r}_g = 0.83$, $SE = 0.01$), number of sexual partners (0.52, $SE = 0.02$), automobile speeding propensity (0.45, $SE = 0.02$), and the first PC of the four risky behaviors (0.50, $SE = 0.02$).

Our estimates of the genetic correlations between general risk tolerance and the supplementary risky behaviors are substantially higher than the corresponding phenotypic correlations (Supplementary Tables 8 and 9). Although measurement error partly accounts for the low phenotypic correlations, the genetic correlations remain considerably higher even after adjustment of the phenotypic correlations for measurement error. The comparatively large genetic correlations support the view that a general factor of risk tolerance partly accounts for cross-domain correlation in risky behavior^{21,22} and imply that this factor is

genetically influenced. The lower phenotypic correlations suggest that environmental factors are more important contributors to domain-specific risky behavior^{23,24}.

To increase the precision of our estimates of the SNPs' effects on general risk tolerance, we leveraged the high degree of genetic overlap across our phenotypes by conducting Multi-Trait Analysis of GWAS (MTAG)¹⁶. We used as inputs the summary statistics of our GWAS of general risk tolerance, of our first five supplementary GWAS (i.e., not including the first PC of the four risky behaviors), and of a previously published GWAS on lifetime cannabis use²⁵ (Supplementary Note). MTAG increased the number of general-risk-tolerance lead SNPs from 124 to 312 (Supplementary Fig. 7 and Supplementary Table 10).

We also estimated genetic correlations between general risk tolerance and 28 additional phenotypes (Fig. 2 and in Supplementary Table 9). These included phenotypes for which we could obtain summary statistics from previous GWAS, as well as five phenotypes for which we conducted new GWAS. The estimated genetic correlations for the personality traits extraversion ($\hat{r}_g = 0.51$, $SE = 0.03$), neuroticism (-0.42 , $SE = 0.04$), and openness to experience (0.33 , $SE = 0.03$) are significantly distinguishable from zero after Bonferroni correction and are substantially larger in magnitude than previously reported phenotypic correlations²⁶, pointing to shared genetic influences among general risk tolerance and these traits. After Bonferroni correction, we also found significant positive genetic correlations with the neuropsychiatric phenotypes ADHD, bipolar disorder, and schizophrenia. Viewed in light of the genetic correlations we found with some supplementary phenotypes and additional risky behaviors classified as externalizing (e.g., substance use, elevated sexual behavior, and fast driving), these results suggest the hypothesis that the overlap with the neuropsychiatric phenotypes is driven by their externalizing component²⁷.

Polygenic prediction

We constructed polygenic scores of general risk tolerance to gauge their potential usefulness in empirical research (Supplementary Note). We used the Add Health, HRS, NTR, STR, UKB-siblings, and Zurich cohorts as validation cohorts (Supplementary Table 5 provides an overview of these cohorts; the UKB-siblings cohort comprised individuals with at least one full sibling in the UKB). For each validation cohort, we constructed the score using summary statistics from a meta-analysis of our discovery and replication GWAS that excluded the cohort (for the UKB-siblings cohort, we reran our UKB GWAS after excluding individuals from that cohort). Our measure of predictive power is the incremental R^2 (or pseudo- R^2) from adding the score to a regression of the phenotype on controls for sex, birth year, and the top ten principal components of the genetic relatedness matrix.

Our preferred score was constructed with LDpred²⁸. Our largest validation cohort ($n \sim 35,000$) is the UKB-siblings cohort. In that validation cohort, the score's predictive power is 1.6% for general risk tolerance, 1.0% for the first PC of the four risky behaviors, 0.8% for number of sexual partners, 0.6% for automobile speeding propensity, and $\sim 0.15\%$ for drinks per week and ever smoker. Across our validation cohorts, in which other phenotypes are measured, the score is also predictive of several personality phenotypes and a suite of real-world measures of risky behaviors in the health, financial, career, and other domains

(Supplementary Figs. 8–9 and Supplementary Tables 11–14). The incremental R^2 we observe for general risk tolerance is consistent with our theoretical prediction, given the GWAS sample sizes, the SNP heritability of general risk tolerance (Table 1), and the imperfect genetic correlations across the GWAS and validation cohorts^{29,30} (Supplementary Note).

Biological annotation

To gain insights into the biological mechanisms through which genetic variation influences general risk tolerance, we conducted a number of bioinformatics analyses using the results of the combined meta-analysis of our discovery and replication GWAS of general risk tolerance.

First, we systematically reviewed the literature that aimed to link risk tolerance to biological pathways (Supplementary Note). Our review covered studies based on candidate genes (i.e., specific genetic variants used as proxies for biological pathways), pharmacological manipulations, biochemical assays, genetic manipulations in rodents, as well as other research designs. Our review identified 132 articles that matched our search criteria (Supplementary Table 1). This previous work has focused on five main biological pathways: the steroid hormone cortisol, the monoamines dopamine and serotonin, and the steroid sex hormones estrogen and testosterone. Using a MAGMA³¹ competitive gene-set analysis, we found no evidence that SNPs within genes associated with these five pathways tend to be more associated with general risk tolerance than SNPs in other genes (Supplementary Table 15). Furthermore, none of the other bioinformatics analyses we report below point to these pathways.

We also examined the 15 most commonly tested autosomal genes within the dopamine and serotonin pathways, which were the focus of most of the 34 candidate-gene studies identified by our literature review. We verified that the SNPs available in our GWAS results tag most of the genetic variants typically used to test the 15 genes. Across one SNP-based test and two gene-based tests, we found no evidence of non-negligible associations between those genes and general risk tolerance (Fig. 1c and Supplementary Table 16). (We note, however, that some brain regions identified in analyses we report below are areas where dopamine and serotonin play important roles.)

Second, we performed a MAGMA³¹ gene analysis to test each of ~18,000 protein-coding genes for association with general risk tolerance (Supplementary Note). After Bonferroni correction, 285 genes were significant (Supplementary Fig. 10 and Supplementary Table 17). To gain insight into the functions and expression patterns of these 285 genes, we looked them up in the Gene Network³² co-expression database.

Third, to identify relevant biological pathways and identify tissues in which genes near general-risk-tolerance-associated SNPs are expressed, we applied the software tool DEPICT³³ to the SNPs with P values less than 10^{-5} in our GWAS of general risk tolerance (Supplementary Note).

Both the Gene Network and the DEPICT analyses separately point to a role for glutamate and GABA neurotransmitters, which are the main excitatory and inhibitory neurotransmitters in the brain, respectively³⁴ (Fig. 3a and Supplementary Tables 18 and 19). To our knowledge, with the exception of a recent study³⁵ prioritizing a much larger number of genes and pathways, no published large-scale GWAS of cognition, personality, or neuropsychiatric phenotypes has pointed to clear roles both for glutamate and GABA (although glutamatergic neurotransmission has been implicated in recent GWAS of schizophrenia³⁶ and major depression³⁷). Our results suggest that the balance between excitatory and inhibitory neurotransmission may contribute to variation in general risk tolerance across individuals.

The Gene Network and the DEPICT tissue enrichment analyses also both separately point to enrichment of the prefrontal cortex and the basal ganglia (Fig. 3b and Supplementary Tables 18, 20, and 21). The cortical and subcortical regions highlighted by DEPICT include some of the major components of the cortical-basal ganglia circuit, which is known as the reward system in human and non-human primates and is critically involved in learning, motivation, and decision-making, notably under risk and uncertainty^{38,39}. We caution, however, that our results do not point exclusively to the reward system.

Lastly, we used stratified LD Score regression⁴⁰ to test for the enrichment of SNPs associated with histone marks in 10 tissue or cell types (Supplementary Note). Central nervous system tissues are the most enriched, accounting for 44% ($SE = 3\%$) of the heritability while comprising only 15% of the SNPs (Supplementary Fig. 11a and Supplementary Table 22). Immune/hematopoietic tissues are also significantly enriched. While a role for the immune system in modulating risk tolerance is plausible given prior evidence of its involvement in several neuropsychiatric disorders^{36,37}, future work is needed to confirm this result and to uncover specific pathways that might be involved.

DISCUSSION:

Our results provide insights into biological mechanisms that influence general risk tolerance. Our bioinformatics analyses point to the role of gene expression in brain regions that have been identified by neuroscientific studies on decision-making, notably the prefrontal cortex, basal ganglia, and midbrain, thereby providing convergent evidence with that from neuroscience^{38,39}. Yet our analyses failed to find evidence for the main biological pathways that had been previously hypothesized to influence risk tolerance. Instead, our analyses implicate genes involved in glutamatergic and GABAergic neurotransmission, which were heretofore not generally believed to play a noteworthy role in risk tolerance.

Although our focus has been on the genetics of general risk tolerance and risky behaviors, environmental and demographic factors account for a substantial share of these phenotypes' variation. We observe sizeable effects of sex and age on general risk tolerance in the UKB data (Supplementary Fig. 4), and life experiences have been shown to affect both measured risk tolerance and risky behaviors (e.g., refs.^{41,42}). The GWAS results we have generated will allow researchers to construct and use polygenic scores of general risk tolerance to measure how environmental, demographic, and genetic factors interact with one another.

For the behavioral sciences, our results bear on an ongoing debate about the extent to which risk tolerance is a “domain-general” as opposed to a “domain-specific” trait. Low phenotypic correlations in risk tolerance across decision-making domains have been interpreted as supporting the domain-specific view^{23,24}. Across the risky behaviors we study, we found that the genetic correlations were considerably higher than the phenotypic correlations (even after the latter are corrected for measurement error) and that many lead SNPs are shared across our phenotypes. These observations suggest that the low phenotypic correlations across domains are due to environmental factors that dilute the effects of a genetically-influenced domain-general factor of risk tolerance.

URLs.

Publicly archived analysis plan for this project, <https://osf.io/cjx9m/>;

Social Science Genetic Association Consortium (SSGAC), <https://www.thessgac.org/data>;

BCFtools, <https://samtools.github.io/bcftools/bcftools.html>;

BEAGLE, <http://faculty.washington.edu/browning/beagle/b3.html>;

BOLT-LMM v.2.3.2, <https://data.broadinstitute.org/alkesgroup/BOLT-LMM/>;

DEPICT (Retrieved Feb 2015), <https://data.broadinstitute.org/mpg/depict/>;

EasyQC v9.0, <http://www.uni-regensburg.de/medizin/epidemiologie-praeventivmedizin/genetische-epidemiologie/software/>;

GCTA, <http://cnsgenomics.com/software/gcta>;

HESS, <http://bogdan.bioinformatics.ucla.edu/software/hess/>;

IMPUTE2, http://mathgen.stats.ox.ac.uk/impute/impute_v2.html;

IMPUTE4, <https://jmarchini.org/impute-4/>;

LD Score Regression (ldsc), <https://github.com/bulik/ldsc/>;

LDpred, https://bitbucket.org/bjarni_vilhjalmsson/ldpred;

Mach2QTL, <http://csg.sph.umich.edu/yli/mach/download/mach2qtl.source.V112.tgz>;

MAGMA, <https://ctg.cncr.nl/software/magma>;

Minimac2, <https://genome.sph.umich.edu/wiki/Minimac2>;

MTAG software, <https://github.com/omeed-maghzian/mtag>;

PBWT, <https://github.com/richarddurbin/pbwt>;

PLINK, <http://zzz.bwh.harvard.edu/plink/plink2.shtml>;

Python v2.7, <https://www.python.org/download/releases/2.7/>;

QCtool v2, http://www.well.ox.ac.uk/~gav/qctool_v2/;

R, <https://www.r-project.org/>;

REGSCAN v0.2.0, <https://www.geenivaramu.ee/en/tools/regscan>;

Rstudio, <https://www.rstudio.com/>;

ShapeIT, http://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html;

SMR, <https://cnsgenomics.com/software/smr/>;

SNPTEST, https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html;

Stata v14.2, <https://www.stata.com/install-guide/windows/download/>.

ONLINE METHODS:

This article is accompanied by a Supplementary Note with further details. Further information on experimental design is also available in the Life Sciences Reporting Summary linked to this article.

Phenotype definitions, GWAS, quality control, and meta-analysis

For our discovery GWAS of general risk tolerance ($n = 939,908$), we performed a sample-size-weighted meta-analysis of results from the UK Biobank (UKB, $n = 431,126$) and a sample of research participants from 23andMe ($n = 508,782$). For our replication GWAS of general risk tolerance ($n = 35,445$), we performed a sample-size-weighted meta-analysis of results from ten smaller cohorts from seven studies: Army STARRS, BASE-II, NFBC 1966, RSIII, STR, UKHLS, and VIKING. The exact measures for the general risk tolerance phenotype vary across cohorts in wording and number of response categories, but all measures are similar and ask about one's tendency, preparedness, or willingness to take risks in general (Supplementary Table 4).

For our GWAS of adventurousness, we analyzed data from a sample of research participants from 23andMe ($n = 557,923$). We analyzed responses to the question: "If forced to choose, would you consider yourself to be more cautious or more adventurous?", with possible responses ranging from "[1] Very cautious" to "[5] Very adventurous." For our GWAS of three of the four risky behaviors—automobile speeding propensity ($n = 404,291$), drinks per week ($n = 414,343$), and number of sexual partners ($n = 370,711$)—and for the first principal component (PC) of the four risky behaviors ($n = 315,894$), we analyzed UKB data. For the remaining risky behavior, ever smoker ($n = 518,633$), we meta-analyzed GWAS results from the UKB and from the TAG Consortium⁴⁴. Our automobile speeding propensity phenotype is based on responses to the question: "How often do you drive faster than the speed limit on the motorway?", with possible responses ranging from "[1] Never/rarely" to "[4] Most of the time." We dropped individuals who answered "[5] Do not drive on the motorway," and then we normalized the categorical variable for males and females separately. Our drinks per

week phenotype was constructed based on responses to a series of questions about drinking habits and is defined as the number of alcoholic drinks consumed per week. Our ever-smoker phenotype in the UKB is a dummy variable that equals one if a respondent reported being a current or previous smoker and zero if the respondent reported never smoking or only smoking once or twice; our ever smoker phenotype from the TAG Consortium is the Consortium's "smoking initiation" phenotype (which TAG also refers to as "ever versus never regular smoker")⁴⁴. Our number of sexual partners phenotype is based on responses to the question: "About how many sexual partners have you had in your lifetime?"; respondents who reported more than 99 lifetime sexual partners were asked to confirm their responses. We assigned a value of zero to participants who reported having never had sex, and we again normalized this measure separately for males and females. Our first PC phenotype is the first PC obtained from a principal component analysis (PCA) in the UKB of the four risky behaviors (Supplementary Table 23). All seven phenotypes were coded such that higher phenotype values are associated with higher risk tolerance or risk taking. Table 1 lists, for each GWAS, the datasets we analyzed and the GWAS sample size. The Supplementary Note and Supplementary Tables 4 and 5 provide additional details on the cohorts and phenotype definitions.

All GWAS were performed at the cohort level in European-ancestry subjects according to a pre-specified and publicly archived analysis plan (see URLs). All GWAS included controls for the top 10 (or more) principal components of the genetic relatedness matrix and for sex and birth year. Genotyping was performed using a range of commercially available genotyping arrays. We applied extensive quality-control (QC) procedures to the cohort-level summary statistics, including but not limited to the EasyQC protocol developed by the GIANT consortium⁴⁵. We used Haplotype Reference Consortium v1.1 (HRC) data to construct our main reference panel, which we used for quality control of the GWAS summary statistics and to determine the independence of significant loci. For the 23andMe and UKB cohorts, only SNPs with minor allele frequency (MAF) greater than 0.001 were analyzed. All meta-analyses were restricted to SNPs with a sample size greater than half of the maximum sample size across all the SNPs in the GWAS. In total, 9,284,738 SNPs were analyzed in the discovery GWAS of general risk tolerance; 9,339,358 SNPs were analyzed in the GWAS of adventurousness; and ~11,515,000 SNPs were analyzed in the GWAS of the four risky behaviors and their first PC. To adjust standard errors for the possible effects of population stratification, we inflated them by the square root of the estimated intercept from an LD Score regression¹² (for the replication GWAS of general risk tolerance, which meta-analyzed different cohorts, we inflated them at the meta-analysis level). Additional details are provided in the Supplementary Note and Supplementary Tables 2 and 24–26.

To identify approximately independent lead SNPs, we applied to the GWAS results a clumping algorithm. Our clumping algorithm begins by selecting the SNP with the lowest P value as the lead SNP in the first clump, and includes in the first clump all SNPs that have r^2 greater than 0.1 with the lead SNP and that have GWAS P value less than 1×10^{-4} . Next, the SNP with the second-lowest P value outside the first clump becomes the lead SNP of the second clump, and the second clump is created analogously but using only the SNPs outside of the first clump. This process continues until every genome-wide significant SNP (i.e., every SNP with a GWAS P value less than 5×10^{-8}) is either designated as a lead SNPs or is

clumped to another lead SNP. We also defined non-overlapping, continuous genomic loci around the lead SNPs using Ripke *et al.*'s⁴⁶ locus definition, and we performed conditional and joint multiple-SNP analyses (COJO)¹³. Ripke *et al.* defined a locus as “the physical region containing all SNPs correlated at $r^2 > 0.6$ with [one of the lead] SNPs”, and merged associated loci within 250 kb of each other. To define the set of distinct loci that contain all the loci corresponding to the locus associations from across the seven GWAS, we pooled the loci corresponding to the locus associations and merged loci within 250 kb from each other. For the COJO analyses, for each of the seven main GWAS we restricted the analysis to the set of SNPs that (1) pass all GWAS quality control filters, and (2) are located within the loci of the phenotype (which includes all of the lead SNPs).

Supplementary Tables 3, 6, 7, and 27 report the lead SNPs, the loci, the results of the COJO analyses, and the results of a lookup of the lead SNPs in the NHGRI-EBI GWAS Catalog database²⁰ for our seven main GWAS; Supplementary Fig. 12 shows the GWAS estimates of general-risk-tolerance lead SNPs in the 23andMe and UKB cohorts and in the replication GWAS, and Supplementary Data 1 shows LocusZoom plots for all the loci identified in the seven GWAS.

Testing for population stratification

To assess the extent to which population stratification may bias our GWAS estimates, we conducted three tests. First, we estimated LD Score intercepts using the summary statistics of the discovery and replication GWAS of general risk tolerance and of the GWAS of our four main risky behaviors and their first PC¹². Second, following Okbay et al. (2016)¹⁰, we conducted sign tests that compare the signs of the estimates from our discovery GWAS of general risk tolerance (but excluding all full siblings from the UKB cohort) to the signs of the estimates from within-family (WF) GWAS of general risk tolerance. If our discovery GWAS estimates were entirely driven by stratification, then the signs of the WF estimates—which are immune to stratification—should be independent of the signs of the discovery GWAS estimates, in which case we would expect a sign concordance of roughly 50%. A higher degree of sign concordance would suggest that at least some of the signal from the GWAS comes from true genetic effects. Across four sign tests, we strongly reject the null hypothesis of 50% sign concordance for all of the sign tests ($P < 5 \times 10^{-10}$ in all four tests), implying that at least some of the signal from the GWAS comes from true genetic effects. Our third test of population stratification, the “within-family regression test,” compares both the signs and magnitudes of the discovery and WF GWAS of general risk tolerance. The Supplementary Note, Supplementary Tables 28, 29, and Supplementary Fig. 13 provide further details on the three tests and report their results. All three tests imply no more than low levels of population stratification.

Replication of the general-risk-tolerance lead SNPs and maxFDR calculation

To assess the credibility of the lead SNPs from our discovery GWAS of general risk tolerance, we compared those results to the estimates from our replication GWAS of general risk tolerance. (We did not attempt replication of the results of our six supplementary GWAS in independent data, because we did not have access to such data for these phenotypes.) We first filtered out SNPs with sample size less than one-half the maximum sample size in the

replication GWAS. After applying this filter, 122 of the 124 lead SNPs were directly available in the replication GWAS summary statistics, and one of the two remaining lead SNPs was well proxied by a SNP in high LD ($r^2 > 0.8$) with it. For the resulting 123 SNPs, we conducted a (one-sided) binomial sign test to assess whether the directions (i.e., the signs) of the effects of the lead SNPs are more concordant across the discovery and the replication GWAS than expected by chance. We also conducted a (one-sided) binomial test to assess whether a larger fraction of the lead SNPs are significant at the 5% level in one-sided tests in the replication GWAS than expected by chance. We then followed the procedure outlined in Okbay *et al.* (2016)⁴⁷ and conducted a Bayesian analysis to obtain estimates of the posterior distributions of the 123 SNPs' true effect sizes (the β_j 's), given their GWAS estimates. We used the SNPs' estimated posterior distributions to estimate their expected replication record in the two binomial tests, and compared their actual and expected replication records.

To calculate the “maxFDR,” an upper bound on the false discovery rate (FDR) for a GWAS, we used the MTAG software¹⁶ and followed the methodology described in section 1.4.3 of Turley *et al.*'s Supplementary Information¹⁶. The maxFDR is defined as the maximum theoretical FDR over a range of possible fractions of null SNPs (π_{null}).

The Supplementary Note and Supplementary Fig. 3 provide additional details.

Estimation of genome-wide SNP heritability

We used the Heritability Estimator from Summary Statistics (HESS)⁴⁸ method to estimate the genome-wide SNP heritability of our seven main phenotypes. For the results reported in Table 1, we used the summary statistics from the GWAS listed in the table for all 1000 Genomes phase 3 SNPs with MAF greater than 0.05. We did not apply GC prior to estimating heritability with HESS. The Supplementary Note, Supplementary Table 30, and Supplementary Fig. 14 provide additional details, and also report estimates of the SNP heritability of our seven main phenotypes estimated with the GCTA⁴⁹, LD Score regression¹², and HESS methods, using only summary statistics from the UKB GWAS for comparability across phenotypes and methods (except for adventurousness, which is not available in the UKB and for which we used the 23andMe summary statistics).

Genetic correlations

We used bivariate LD Score regression⁹ to estimate genetic correlations between general risk tolerance and various phenotypes. We used the scores computed by Finucane *et al.*⁵⁰, which are based on genotypic data from the European-ancestry samples in the 1000 Genomes Project and only HapMap3 SNPs. As is common in the literature, we restricted our analyses to SNPs with MAF > 0.01. We used the summary statistics of the meta-analysis combining our discovery and replication GWAS of general risk tolerance to estimate genetic correlations with general risk tolerance, and we used the summary statistics of our GWAS of adventurousness, our four main risky behaviors, and their first PC to estimate genetic correlations with those phenotypes. For most other phenotypes, we used published GWAS results. We obtained the summary statistics from the GWAS of lifetime cannabis use²⁵ and of ADHD⁵¹ from the International Cannabis Consortium and the Psychiatric Genomics

Consortium, respectively. We conducted our own GWAS using the first release of the UKB data for five phenotypes: age first had sexual intercourse ($n = 98,956$), teenage conception among females ($n = 40,077$), use of sun protection ($n = 111,560$), household income ($n = 97,059$), and Townsend deprivation index score ($n = 112,192$). The sex-specific GWAS of general risk tolerance used to estimate the genetic correlation between males and females were conducted in the full release of UKB data, separately for males and females, following the same methodology and QC protocol as for our other GWAS in the full release of UKB data. The Supplementary Note and Supplementary Tables 9, 31 provide additional details. Also, the Supplementary Note, Supplementary Table 32, and Supplementary Fig. 15 report the results of proxy-phenotype analyses in which we examined whether the general-risk-tolerance lead SNPs tend to also be associated with related phenotypes.

Multi-trait analysis of GWAS (MTAG)

We used Multi-Trait Analysis of GWAS (MTAG)¹⁶ to increase the precision of our estimates of the SNPs' effects on general risk tolerance. We used as inputs the summary statistics of the meta-analysis combining our discovery and replication GWAS of general risk tolerance; the summary statistics of our GWAS of adventurousness, automobile speeding propensity, drinks per week, ever smoker, and number of sexual partners; and the summary statistics of a previously published GWAS on lifetime cannabis use⁵². Because SNPs that have no effect on one phenotype but a sizeable effect on another can bias MTAG results, we excluded from this analysis SNPs in the proximity of several genes implicated in biological processes that are likely to be specific only to one of the phenotypes. Specifically, we excluded all SNPs located within 1Mb of the genes *CHRNA5* and *CHRNA3* (nicotinic receptors), *CNR1* and *CNR2* (cannabinoid receptors), and *ADH1B* (Alcohol Dehydrogenase). We imposed a MAF filter of 0.01 and a sample size filter that selected, for each GWAS, the SNPs with sample sizes larger than two-thirds of the ninth decile of the GWAS's sample size. MTAG limited the analysis to the 5,869,552 SNPs analyzed in all GWAS (and that satisfied these filters). To identify approximately independent lead SNPs for general risk tolerance, we applied the clumping algorithm described above. The Supplementary Note, Supplementary Table 10, and Supplementary Fig. 7 provide further details.

Polygenic prediction

We assessed the predictive power of polygenic scores of general risk tolerance in six different validation cohorts: Add Health, HRS, NTR, STR, UKB-siblings, and Zurich. (The UKB-siblings cohort comprised all individuals with at least one full sibling in the UKB.) We constructed three polygenic scores. Our first two polygenic scores were constructed with the LDpred²⁸ method, which accounts for the linkage disequilibrium (LD) between SNPs. The first used the summary statistics from the meta-analysis of the discovery and replication GWAS of general risk tolerance, while the second used the MTAG summary statistics. (The LDpred method relies on a Gaussian mixture weight that corresponds to the assumed fraction of SNPs that are causal. For each of our first two polygenic scores, we first generated LDpred scores for each of the following mixture weights: 1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001, 0.0003, and 0.0001⁵³. The LDpred-score results we present in this paper for our first two polygenic scores are for the scores based on a Gaussian mixture weight of 0.3 (our "preferred score"), which consistently performed well across cohorts and phenotypes.)

Our third polygenic score was constructed with the classical method, which simply weights SNPs by their GWAS effect size^{54,55}, using the summary statistics from the meta-analysis of the discovery and replication GWAS of general risk tolerance.

We used the subset of all the SNPs (i.e., we did not impose a P value threshold) in the HapMap consortium phase 3 release⁵⁶ with an imputation quality of more than 0.7 to generate all three scores. For every validation cohort that was also included in the discovery or replication GWAS or in the MTAG analysis, we reran the GWAS and MTAG analyses without the validation cohort to generate the summary statistics we used to construct the scores. Due to data access limitations, the 23andMe cohort could not be included in the meta-analysis whose summary statistics we used to construct the polygenic scores in the NTR, STR, and Zurich cohorts. The second polygenic score (using the MTAG summary statistics) was only constructed for the Add Health, HRS, and UKB-siblings cohorts.

Our measure of a score's predictive power for a predicted phenotype is the incremental R^2 (or incremental pseudo- R^2) from adding the score to a regression of the phenotype on controls for sex, birth year, birth-year squared, birth-year cubed, as well as the interactions between sex and the three birth-year variables, and the first ten principal components of the genetic relatedness matrix. We used the bootstrap method with 1,000 iterations to estimate 95% percentile confidence intervals for the incremental R^2 estimates. For continuous phenotypes, we estimated ordinary least squares (OLS) regressions; for binary phenotypes (e.g., ever smoker), we estimated probit models; and for censored phenotypes (e.g., equity share, which is nonnegative), we estimated tobit models. For binary and censored phenotypes, we used McFadden's pseudo- R^2 to calculate the incremental pseudo- R^2 .

The Supplementary Note provides additional details, including a description of how the predicted phenotypes were constructed. Results are presented in Supplementary Figs. 8–9 and Supplementary Tables 11–14.

Biological annotation: testing hypotheses about specific genes and gene sets

We conducted a comprehensive review of the literature on biological pathways that have been hypothesized to influence risk tolerance. The 132 articles identified by review are compiled in Supplementary Table 1. The Supplementary Note and Supplementary Tables 15, 16, and 33–34 provide further details and report the results of the various analyses we conducted to assess whether the pathways and genes that have previously been hypothesized to relate to risk tolerance do indeed show evidence of association with risk tolerance.

Biological annotation: additional bioinformatics analyses

We conducted a series of additional bioinformatics analyses using the results of the combined meta-analysis of our discovery and replication GWAS of general risk tolerance. We conducted a gene analysis with MAGMA³¹ to test each of 18,224 genes for association with general risk tolerance in a hypothesis-free manner (the 18,224 genes are the set of all genes containing at least one SNP in our combined meta-analysis results). We used our main reference panel to estimate LD. Bonferroni correction was applied to account for multiple testing, counting each gene as an independent test. We then used the Gene Network³² co-expression database to gain insight into the functions of the significant MAGMA genes.

We also used DEPICT³³ (release 194) to prioritize tissues, gene sets, and genes that are implicated by our GWAS results. Only SNPs with GWAS P values less than 10^{-5} were used as input, and DEPICT-defined loci were defined by clumping these SNPs (see the Supplementary Note for the clumping parameters used for this analysis). Locus boundaries were then defined using a LD r^2 threshold of 0.5, and overlapping loci were merged, yielding 464 autosomal loci comprising 1,060 genes.

To partition the SNP-based heritability of general risk tolerance, we used stratified LD Score regression⁵⁰, following the procedure described by Finucane *et al.*⁵⁰. We estimated stratified LD Score regressions both for the functional genomic regions of the “baseline model” and for the tissue-level annotations provided by Finucane *et al.* To correct for multiple hypothesis testing, we applied a Bonferroni correction for 52 two-sided tests in the baseline model (i.e., for 52 annotations) and for 10 two-sided tests in the tissue type models (i.e., for 10 tissue types).

The Supplementary Note, Supplementary Tables 17–22 and 35–39, and Supplementary Figs. 10–11 and 16 provide further details and report the results of these and other bioinformatics analyses, including a transcriptome-wide analysis with Summary-based Mendelian Randomization (SMR)⁵⁷, and an ascertainment of whether the lead SNPs and their LD partners (SNPs with an $r^2 > 0.6$ with a lead SNP and no more than 250 kb from it) are protein-altering variants or are associated with *cis*-gene expression in distinct human tissues, among other analyses. The Supplementary Note also highlights the most important results of the bioinformatics analyses and summarizes the conclusions we derive from them.

DATA AVAILABILITY STATEMENT:

GWAS summary statistics can be downloaded from www.thessgac.org/data. SNP-level summary statistics from analyses based entirely or in part on 23andMe data can only be reported for up to 10,000 SNPs. For general risk tolerance, we provide association results for all SNPs that passed quality-control filters in a GWAS meta-analysis of general risk tolerance that excludes the research participants from 23andMe; we also provide association results from the complete GWAS (which includes data from 23andMe) for all lead SNPs identified in our discovery GWAS and MTAG analysis of general risk tolerance, and for the next 4,000 most significant SNPs in the discovery GWAS. For adventurousness, we provide association results from the complete GWAS (which includes only data from 23andMe) for all lead SNPs and for the next 4,000 most significant SNPs. For automobile speeding propensity, drinks per week, ever smoker, number of sexual partners, and the first PC of the four risky behaviors, we provide association results from the complete GWAS for all SNPs that passed quality-control filters. Contact information for the cohorts included in this paper can be found in the Supplementary Note.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Richard Karlsson Linnér^{1,2,3,90,*}, Pietro Biroli^{4,90}, Edward Kong^{5,90}, S Fleur W Meddens^{1,2,3,90}, Robbee Wedow^{6,7,8,9,90}, Mark Alan Fontana^{10,11}, Maël Lebreton^{12,13}, Stephen P Tino¹⁴, Abdel Abdellaoui¹⁵, Anke R Hammerschlag¹, Michel G Nivard¹⁵, Aysu Okbay^{1,3}, Cornelius A Rietveld^{2,16,17}, Pascal N Timshel^{18,19}, Maciej Trzaskowski²⁰, Ronald de Vlaming^{1,2,3}, Christian L Zünd⁴, Yanchun Bao²¹, Laura Buzdugan^{22,23}, Ann H Caplin²⁴, Chia-Yen Chen^{6,8,25}, Peter Eibich^{26,27,28}, Pierre Fontanillas²⁹, Juan R Gonzalez^{30,31,32}, Peter K Joshi³³, Ville Karhunen³⁴, Aaron Kleinman²⁹, Remy Z Levin³⁵, Christina M Lill³⁶, Gerardus A Meddens³⁷, Gerard Muntané^{38,39,40}, Sandra Sanchez-Roige⁴¹, Frank J van Rooij¹⁷, Erdogan Taskesen¹, Yang Wu²⁰, Futao Zhang²⁰, 23andMe Research Team⁴², eQTLgen Consortium⁴², International Cannabis Consortium⁴³, Social Science Genetic Association Consortium⁴², Adam Auton²⁹, Jason D Boardman^{44,45,46}, David W Clark³³, Andrew Conlin⁴⁷, Conor C Dolan¹⁵, Urs Fischbacher^{48,49}, Patrick J F Groenen^{2,50}, Kathleen Mullan Harris^{51,52}, Gregor Hasler⁵³, Albert Hofman^{7,17}, Mohammad A Ikram¹⁷, Sonia Jain⁵⁴, Robert Karlsson⁵⁵, Ronald C Kessler⁵⁶, Maarten Kooyman⁵⁷, James MacKillop^{58,59}, Minna Männikkö³⁴, Carlos Morcillo-Suarez³⁸, Matthew B McQueen⁶⁰, Klaus M Schmidt⁶¹, Melissa C Smart²¹, Matthias Sutter^{62,63,64}, A Roy Thurik^{2,65}, André G Uitterlinden⁶⁶, Jon White⁶⁷, Harriet de Wit⁶⁸, Jian Yang^{20,69}, Lars Bertram^{36,70,71}, Dorret I Boomsma¹⁵, Tõnu Esko⁷², Ernst Fehr²³, David A Hinds²⁹, Magnus Johannesson⁷³, Meena Kumari²¹, David Laibson⁵, Patrik K E Magnusson⁵⁵, Michelle N Meyer⁷⁴, Arcadi Navarro^{38,75,76}, Abraham A Palmer^{41,77}, Tune H Pers^{18,19}, Danielle Posthuma^{1,78}, Daniel Schunk⁷⁹, Murray B Stein^{41,54}, Rauli Svento⁴⁷, Henning Tiemeier¹⁷, Paul R H J Timmers³³, Patrick Turley^{6,8,80}, Robert J Ursano⁸¹, Gert G Wagner^{27,82}, James F Wilson^{33,83}, Jacob Gratten^{20,84}, James J Lee⁸⁵, David Cesarini⁸⁶, Daniel J Benjamin^{80,87,88,91}, Philipp D Koellinger^{1,3,89,91}, Jonathan P Beauchamp^{14,91,*}

Affiliations

¹Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam, De Boelelaan 1085, Amsterdam, 1081 HV, The Netherlands ²Erasmus University Rotterdam Institute for Behavior and Biology, Erasmus School of Economics, Erasmus University Rotterdam, Burgemeester Oudlaan 50, Rotterdam, 3062 PA Rotterdam, The Netherlands ³Department of Economics, VU University Amsterdam, De Boelelaan 1105, Amsterdam, 1081 HV, The Netherlands ⁴Department of Economics, University of Zurich, Schönberggasse 1, Zurich, 8001, Switzerland ⁵Department of Economics, Harvard University, 1805 Cambridge St, Cambridge, MA 02138, USA ⁶Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA ⁷Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA ⁸Analytic Translational Genetics Unit, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA ⁹Department of Sociology, Harvard University, Cambridge, MA 02138, USA ¹⁰Center for the Advancement of Value in Musculoskeletal Care,

Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
¹¹Department of Healthcare Policy and Research, Weill Cornell Medical College, Cornell University, 402 East 67th Street, New York, NY, 10065 ¹²Amsterdam School of Economics, University of Amsterdam, Roetersstraat 11, Amsterdam, 1018 WB, The Netherlands ¹³Amsterdam Brain and Cognition, University of Amsterdam, Nieuwe Achtergracht 129B, Amsterdam, 1001 NK, Netherlands ¹⁴Department of Economics, University of Toronto, 150 St. George St., Toronto, Ontario, M5S 3G7, Canada ¹⁵Biological Psychology, Vrije Universiteit Amsterdam, van der Boechorstraat 1, Amsterdam, 1087 BT, The Netherlands ¹⁶Department of Applied Economics, Erasmus School of Economics, Erasmus University Rotterdam, Burgemeester Oudlaan 50, Rotterdam, 3062 PA, The Netherlands ¹⁷Department of Epidemiology, Erasmus Medical Center, Wytemaweg 80, Rotterdam, 3015 GE, The Netherlands ¹⁸Novo Nordisk Foundation Centre for Basic Metabolic Research, University of Copenhagen, Copenhagen, 2200, Denmark ¹⁹Department of Epidemiology Research, Statens Serum Institut, Copenhagen, 2300, Denmark ²⁰Institute for Molecular Bioscience, The University of Queensland, Brisbane, 4072, Australia ²¹Institute for Social & Economic Research, University of Essex, Wivenhoe Park, Colchester, CO4 3SQ, UK ²²Seminar for Statistics, Department of Mathematics, ETH Zurich, Raemistrasse 101, Zurich, 8092, Switzerland ²³Department of Economics, University of Zurich, Bluemlisalpstrasse 10, Zurich, 8006, Switzerland ²⁴Stuyvesant High School, New York, NY 10282, USA ²⁵Psychiatric & Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA 02114, USA ²⁶Nuffield Department of Population Health, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK ²⁷Socio-Economic Panel Study, DIW Berlin, Mohrenstr. 58, Berlin, 10117, Germany ²⁸Max Planck Institute for Demographic Research, Konrad-Zuse-Str. 1, Rostock, 18057, Germany ²⁹Research, 23andMe, Inc., 899 W Evelyn Ave, Mountain View, CA 94041, USA ³⁰Barcelona Institute for Global Health (ISGlobal), Barcelona, 8003, Spain ³¹Universitat Pompeu Fabra (UPF), Barcelona, 8003, Spain ³²CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, 280229, Spain ³³Centre for Global Health Research, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG, Scotland ³⁴Center for Life Course Health Research, University of Oulu, Aapistie 5, Oulu, 90220, Finland ³⁵Department of Economics, University of California San Diego, La Jolla, CA 92093, USA ³⁶Genetic and Molecular Epidemiology Group, Lübeck Interdisciplinary Platform for Genome Analytics, Institutes of Neurogenetics & Cardiogenetics, University of Lübeck, Maria-Goeppert-Str. 1, Lübeck, 23562, Germany ³⁷Team Loyalty BV, Debbemeerstraat 25, Hoofddorp, 2131 HE, The Netherlands ³⁸Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Dr. Aiguader, 88, Barcelona, 8003, Spain ³⁹Research Department, Hospital Universitari Institut Pere Mata, Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, E43206, Spain ⁴⁰Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Reus, E43204, Spain ⁴¹Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA ⁴²A list of members and affiliations appears

at the end of the paper. ⁴³A list of members and affiliations appears in the Supplementary Information. ⁴⁴Institute for Behavioral Genetics, University of Colorado Boulder, 1480 30th Street, Boulder, CO 80309, USA ⁴⁵Institute of Behavioral Science, University of Colorado Boulder, 1440 15th Street, Boulder, CO 80309, USA ⁴⁶Department of Sociology, University of Colorado Boulder, UCB 327, Boulder, CO 80309, USA ⁴⁷Department of Economics and Finance, Oulu Business School, University of Oulu, Oulu, 90570, Finland ⁴⁸Department of Economics, University of Konstanz, Universitätsstraße 10, Konstanz, 78457, Germany ⁴⁹Thurgau Institute of Economics, Hauptstrasse 90, Kreuzlingen, 8280, Switzerland ⁵⁰Department of Econometrics, Erasmus University Rotterdam, Burgemeester Oudlaan 50, Rotterdam, 3062 PA Rotterdam, The Netherlands ⁵¹Department of Sociology, University of North Carolina at Chapel Hill, 201 Hamilton Hall CB #3210, Chapel Hill, NC 27599, USA ⁵²Carolina Population Center, University of North Carolina at Chapel Hill, 123 West Franklin St., Suite 2190, Chapel Hill, NC 27516, USA ⁵³Unit of Psychiatry Research, University of Fribourg, Chemin du Cardinal-Journet 3, 1752 Villars-sur-Glâne, Fribourg, Switzerland ⁵⁴Family Medicine and Public Health, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA ⁵⁵Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12a, Stockholm, 171 77, Sweden ⁵⁶Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave., Boston, MA 02115, USA ⁵⁷SURFsara, Science Park 140, Amsterdam, 1098 XG, The Netherlands ⁵⁸Peter Boris Centre for Addictions Research, McMaster University/St. Joseph's Healthcare Hamilton, 100 West 5th Street, Hamilton, Ontario, L8P 3R2, Canada ⁵⁹Homewood Research Institute, 150 Delhi Street, Riverslea Building, Guelph, Ontario, N1E 6K9, Canada ⁶⁰Department of Integrative Physiology, University of Colorado Boulder, 354 UCB, Boulder, CO 80309, USA ⁶¹Department of Economics, University of Munich, Ludwigstrasse 28, Munich, 80539, Germany ⁶²Department of Economics, University of Cologne, Albert-Magnus-Platz, Cologne, 50923, Germany ⁶³Experimental Economics Group, Max Planck Institute for Research into Collective Goods, Schumacher Strasse 10, Bonn, D-51113, Germany ⁶⁴Department of Public Finance, University of Innsbruck, Universitaetsstrasse 15, Innsbruck, A-6020, Austria ⁶⁵Montpellier Business School, Montpellier, 34080, France ⁶⁶Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands ⁶⁷UCL Genetics Institute, Department of Genetics, Evolution and Environment, University College London, Darwin Building, Gower Street, London, WC1E 6BT, UK ⁶⁸Psychiatry and Behavioral Neuroscience, University of Chicago, 5841 S. Maryland Ave., Chicago, IL 60637, USA ⁶⁹Queensland Brain Institute, The University of Queensland, Brisbane, 4072, Australia ⁷⁰Dept of Psychology, University of Oslo, Forskningsveien 3A, 0373 Oslo, Norway ⁷¹School of Public Health, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK ⁷²Estonian Genome Center, University of Tartu, Tartu, 51010, Estonia ⁷³Department of Economics, Stockholm School of Economics, Box 6501, Stockholm, 113 83, Sweden ⁷⁴Center for Translational Bioethics and Health Care Policy, Geisinger Health System, Danville, PA 17822, USA ⁷⁵Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST),

Baldiri i Reixac 4, 08028 Barcelona, Spain ⁷⁶Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia 08010, Spain ⁷⁷Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 92093, USA ⁷⁸Department of Clinical Genetics, VU Medical Centre, De Boelelaan 1085, Amsterdam, 1081 HV, The Netherlands ⁷⁹Department of Economics, Johannes Gutenberg University, Jakob-Welder-Weg 4, Mainz, 55128, Germany ⁸⁰Behavioral and Health Genomics Center, Center for Economic and Social Research, University of Southern California, 635 Downey Way, Los Angeles, CA 90089, USA ⁸¹Department of Psychiatry, Center for the Study of Traumatic Stress, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA ⁸²Max Planck Institute for Human Development, Lentzeallee 94, Berlin, 14195, Germany ⁸³MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU, Scotland ⁸⁴Mater Medical Research Institute, Translational Research Institute, Brisbane 4102, Australia ⁸⁵Department of Psychology, University of Minnesota Twin Cities, 75 East River Parkway, Minneapolis, MN 55455, USA ⁸⁶Department of Economics, New York University, 19 W 4th St, 6 FL, NY 10012, USA ⁸⁷Department of Economics, University of Southern California, Kaprielian Hall, 3620 S. Vermont Ave, Los Angeles, CA 90089 ⁸⁸National Bureau of Economic Research, 1050 Massachusetts Ave, Cambridge, MA 02138, USA ⁸⁹German Institute for Economic Research, DIW Berlin, Mohrenstr. 58, Berlin, 10117, Germany ⁹⁰These authors contributed equally: Richard Karlsson Linnér, Pietro Biroli, Edward Kong, S Fleur W Meddens, and Robbee Wedow; lead analysts 2-5 are listed alphabetically. ⁹¹These authors jointly supervised this work: Daniel J Benjamin, Philipp D Koellinger, and Jonathan P Beauchamp.

ACKNOWLEDGEMENTS:

This research was carried out under the auspices of the Social Science Genetic Association Consortium (SSGAC). The research has also been conducted using the UK Biobank Resource under Application Number 11425. The study was supported by funding from the Ragnar Söderberg Foundation (E9/11 and E42/15), the Swedish Research Council (421-2013-1061), The Jan Wallander and Tom Hedelius Foundation, an ERC Consolidator Grant to Philipp Koellinger (647648 EdGe), the Pershing Square Fund of the Foundations of Human Behavior, the Open Philanthropy Project, the NIA/NIH through grants P01-AG005842, P01-AG005842-20S2, P30-AG012810, and T32-AG000186-23 to NBER, and R01-AG042568-02 to the University of Southern California, the Government of Canada through Genome Canada and the Ontario Genomics Institute (OGI-152), and the Social Sciences and Humanities Research Council of Canada. We thank the International Cannabis Consortium, the eQTLgen Consortium, and the Psychiatric Genomics Consortium, for sharing summary statistics from the GWAS of lifetime cannabis use, eQTL summary statistics, and summary statistics from the GWAS of ADHD, respectively. A full list of acknowledgments is provided in the Supplementary Note.

COMPETING FINANCIAL INTERESTS STATEMENT:

Adam Auton, Pierre Fontanillas, David A Hinds, and Aaron Kleinman are employees of 23andMe. Ronald C Kessler, in the past three years, received support for his epidemiological studies from Sanofi Aventis; was a consultant for Johnson & Johnson Wellness and Prevention, Sage Pharmaceuticals, Shire, Takeda; and served on an advisory board for the Johnson & Johnson Services Inc. Lake Nona Life Project. Kessler is a co-owner of DataStat, Inc., a market research firm that carries out healthcare research. James MacKillop is a principal in BEAM Diagnostics, Inc. The authors declare no other competing financial interests.

REFERENCES:

1. Dohmen T et al. Individual risk attitudes: Measurement, determinants, and behavioral consequences. *J. Eur. Econ. Assoc* 9, 522–550 (2011).
2. Falk A, Dohmen T, Falk A & Huffman D The nature and predictive power of preferences: Global evidence. *IZA Discuss. Pap* (2015).
3. Beauchamp JP, Cesarini D & Johannesson M The psychometric and empirical properties of measures of risk preferences. *J. Risk Uncertain* 54, 203–237 (2017).
4. Cesarini D, Dawes CT, Johannesson M, Lichtenstein P & Wallace B Genetic variation in preferences for giving and risk taking. *Q. J. Econ* 124, 809–842 (2009).
5. Harden KP et al. Beyond dual systems: A genetically-informed, latent factor model of behavioral and self-report measures related to adolescent risk-taking. *Dev. Cogn. Neurosci* 25, 221–234 (2017). [PubMed: 28082127]
6. Hewitt JK Editorial policy on candidate gene association and candidate gene-by-environment interaction studies of complex traits. *Behav. Genet* 42, 1–2 (2012). [PubMed: 21928046]
7. Day FR et al. Physical and neurobehavioral determinants of reproductive onset and success. *Nat. Genet* 48, 617–623 (2016). [PubMed: 27089180]
8. Strawbridge RJ et al. Genome-wide analysis of self-reported risk-taking behaviour and cross-disorder genetic correlations in the UK Biobank cohort. *Transl. Psychiatry* 8, 1–11 (2018). [PubMed: 29317594]
9. Bulik-Sullivan BK et al. An atlas of genetic correlations across human diseases and traits. *Nat. Genet* 47, 1236–1241 (2015). [PubMed: 26414676]
10. Okbay A et al. Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. *Nat. Genet* 48, 624–633 (2016). [PubMed: 27089181]
11. Bulik-Sullivan BK et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet* 47, 291–295 (2015). [PubMed: 25642630]
12. Bulik-Sullivan BK et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet* 47, 291–295 (2015). [PubMed: 25642630]
13. Yang J et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet* 44, 369–375 (2012). [PubMed: 22426310]
14. Byrnes JP, Miller DC & Schafer WD Gender differences in risk taking: a meta-analysis. *Psychol. Bull* 125, 367–383 (1999).
15. Croson R & Gneezy U Gender Differences in Preferences. *J. Econ. Lit* 47, 448–474 (2009).
16. Turley P et al. Multi-trait analysis of genome-wide association summary statistics using MTAG. *Nat. Genet* 50, 229–237 (2018). [PubMed: 29292387]
17. Shi H, Kichaev G & Pasaniuc B Contrasting the genetic architecture of 30 complex traits from summary association data. *bioRxiv* 99, 1–28 (2016).
18. Price AL et al. Long-range LD can confound genome scans in admixed populations. *Am. J. Hum. Genet* 83, 132–139 (2008). [PubMed: 18606306]
19. Berisa T & Pickrell JK Approximately independent linkage disequilibrium blocks in human populations. *Bioinformatics* 32, 283–285 (2016). [PubMed: 26395773]
20. Welter D et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res* 42, D1001–1006 (2014). [PubMed: 24316577]
21. Einav BL, Finkelstein A, Pascu I & Cullen MR How general are risk preferences? Choices under uncertainty in different domains. *Am. Econ. Rev* 102, 2606–2638 (2016).
22. Frey R, Pedroni A, Mata R, Rieskamp J & Hertwig R Risk preference shares the psychometric structure of major psychological traits. *Sci. Adv* 3, e1701381 (2017). [PubMed: 28983511]
23. Weber EU, Blais AE & Betz NE A domain-specific risk-attitude scale: Measuring risk perceptions and risk behaviors. *J. Behav. Decis. Mak. J. Behav. Dec. Mak* 15, 263–290 (2002).

24. Hanoch Y, Johnson JG & Wilke A Domain specificity in experimental measures and participant recruitment: an application to risk-taking behavior. *Psychol. Sci* 17, 300–304 (2006). [PubMed: 16623686]
25. Stringer S et al. Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32,330 subjects from the International Cannabis Consortium. *Transl. Psychiatry* 6, e769 (2016). [PubMed: 27023175]
26. Becker A, Deckers T, Dohmen T, Falk A & Kosse F The relationship between economic preferences and psychological personality measures. *Annu. Rev. Econom* 4, 453–478 (2012).
27. Krueger RF et al. Etiologic connections among substance dependence, antisocial behavior and personality: Modeling the externalizing spectrum. *J. Abnorm. Psychol* 111, 411–424 (2002). [PubMed: 12150417]
28. Vilhjálmsson BJ et al. Modeling linkage disequilibrium increases accuracy of polygenic risk scores. *Am. J. Hum. Genet* 97, 576–592 (2015). [PubMed: 26430803]
29. Daetwyler HD, Villanueva B & Woolliams JA Accuracy of predicting the genetic risk of disease using a genome-wide approach. *PLoS One* 3, e3395 (2008). [PubMed: 18852893]
30. de Vlaming R et al. Meta-GWAS Accuracy and Power (MetaGAP) calculator shows that hiding heritability is partially due to imperfect genetic correlations across studies. *PLoS Genet* 13, e1006495 (2017). [PubMed: 28095416]
31. de Leeuw CA, Mooij JM, Heskes T & Posthuma D MAGMA: Generalized gene-set analysis of GWAS data. *PLoS Comput. Biol* 11, 1–19 (2015).
32. Fehrmann RSN et al. Gene expression analysis identifies global gene dosage sensitivity in cancer. *Nat. Genet* 47, 115–125 (2015). [PubMed: 25581432]
33. Pers TH et al. Biological interpretation of genome-wide association studies using predicted gene functions. *Nat. Commun* 6, 5890 (2015). [PubMed: 25597830]
34. Petroff OAC GABA and glutamate in the human brain. *Neurosci* 8, 562–573 (2002).
35. Lee J et al. Gene discovery and polygenic prediction from a 1.1-million-person GWAS of educational attainment. *Nat. Genet* 50, 1112–1121 (2018). [PubMed: 30038396]
36. Ripke S et al. Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 511, 421–427 (2014). [PubMed: 25056061]
37. Wray NR et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *bioRxiv* (2017). doi:10.1101/167577
38. Haber SN & Knutson B The reward circuit: linking primate anatomy and human imaging. *Neuropsychopharmacology* 35, 4–26 (2010). [PubMed: 19812543]
39. Tobler PN & Weber EU in *Neuroeconomics* 149–172 (Elsevier, 2014). doi:10.1016/B978-0-12-416008-8.00009-7
40. Finucane HK et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat. Genet* 47, 1228–1235 (2015). [PubMed: 26414678]
41. Sahn CR How much does risk tolerance change? *Q. J. Financ* 2, 1250020 (2012).
42. Malmendier U & Nagel S Depression babies: Do macroeconomic experiences affect risk taking? *Q. J. Econ* 126, 373–416 (2011).
43. Frey BJ & Dueck D Clustering by passing messages between data points. *Science* 315, (2007).

METHODS-ONLY REFERENCES:

44. Furberg H et al. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. *Nat. Genet* 42, 441–447 (2010). [PubMed: 20418890]
45. Winkler TW et al. Quality control and conduct of genome-wide association meta-analyses. *Nat. Protoc* 9, 1192–212 (2014). [PubMed: 24762786]
46. Ripke S et al. Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 511, 421–427 (2014). [PubMed: 25056061]
47. Okbay A et al. Genome-wide association study identifies 74 loci associated with educational attainment. *Nature* 533, 539–542 (2016). [PubMed: 27225129]

48. Shi H, Kichaev G & Pasaniuc B Contrasting the genetic architecture of 30 complex traits from summary association data. *Am. J. Hum. Genet* 99, 139–153 (2016). [PubMed: 27346688]
49. Yang J, Lee SH, Goddard ME & Visscher PM GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet* 88, 76–82 (2011). [PubMed: 21167468]
50. Finucane HK et al. Partitioning heritability by functional category using GWAS summary statistics. *Nat. Genet* 47, 1228–1235 (2015). [PubMed: 26414678]
51. Demontis D et al. Discovery of the first genome-wide significant risk loci for ADHD. *bioRxiv* (2017). doi:10.1101/145581
52. Stringer S et al. Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium. *Transl. Psychiatry* 6, e769 (2016). [PubMed: 27023175]
53. Vilhjálmsson BJ et al. Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. *Am. J. Hum. Genet* 97, 576–592 (2015). [PubMed: 26430803]
54. Dudbridge F Power and predictive accuracy of polygenic risk scores. *PLoS Genet* 9, e1003348 (2013). [PubMed: 23555274]
55. Purcell SM et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* 460, 748–752 (2009). [PubMed: 19571811]
56. Buchanan CC, Torstenson ES, Bush WS & Ritchie MD A comparison of cataloged variation between International HapMap Consortium and 1000 Genomes Project data. *J. Am. Med. Informatics Assoc* 19, 289–294 (2012).
57. Zhu Z et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat. Genet* 48, 481–7 (2016). [PubMed: 27019110]




Figure 1 |. Manhattan plots.

In all panels, the x -axis is chromosomal position; the y -axis is the GWAS P value on a $-\log_{10}$ scale (based on a two-tailed z -test); each lead SNP is marked by a red “x”; each conditional association is marked by a red “o”; and each SNP that is both a lead SNP and a conditional association is marked by a red “⊗”. **a**, Manhattan plots for the discovery GWAS of general risk tolerance ($n = 939,908$). **b**, Local Manhattan plots of a long-range LD region on chromosome 3 and a candidate inversion on chromosome 18 that contain lead SNPs for all seven of our GWAS. The gray background marks the locations of long-range LD or candidate inversion regions. **c**, Local Manhattan plots of the areas around the 15 most commonly tested candidate genes in the prior literature on the genetics of risk tolerance. Each local plot shows all SNPs within 500 kb of the gene’s borders that are in weak LD ($r^2 > 0.1$) with a SNP in the gene. The 15 plots are concatenated and shown together in the panel, divided by the black vertical lines. The 15 genes are not particularly strongly

associated with general risk tolerance or the risky behaviors, as can be seen by comparing the results within each row across panels **b** and **c** (the three rows correspond to the GWAS of general risk tolerance, adventurousness ($n = 557,923$), and the first PC of the four risky behaviors ($n = 315,894$)).




Figure 2 |. Genetic correlations with general risk tolerance.

The genetic correlations were estimated using bivariate LD Score (LDSC) regression⁹. Error bars show 95% confidence intervals. For the supplementary phenotypes and the additional risky behaviors, green bars represent significant estimates with the expected signs, where higher risk tolerance is associated with riskier behavior. For the other phenotypes, blue bars represent significant estimates. Light green and light blue bars represent genetic correlations that are statistically significant at the 5% level, and dark green and dark blue bars represent correlations that are statistically significant after Bonferroni correction for 35 tests (the total number of phenotypes tested). Grey bars represent correlations that are not statistically significant at the 5% level. The two dotted vertical lines indicate genetic correlations of -0.5 and 0.5 , respectively. All significance tests are two-sided.




Figure 3 | Results from selected biological analyses.

a, DEPICT gene-set enrichment diagram. We identified 93 reconstituted gene sets that are significantly enriched (FDR < 0.01) for genes overlapping DEPICT-defined loci associated with general risk tolerance; using the Affinity Propagation method⁴³, these were grouped into the 13 clusters displayed in the graph. Each cluster was named after its exemplary gene set, as chosen by the Affinity Propagation tool, and each cluster's color represents the permutation P value of its most significant gene set. The “synapse part” cluster includes the gene set “glutamate receptor activity,” and several members of the “GABA_A receptor activation” cluster are defined by gamma-aminobutyric acid signaling. Overlap between the named representatives of two clusters is represented by an edge. Edge width represents the Pearson correlation ρ between the two respective vectors of gene membership scores ($\rho < 0.3$, no edge; $0.3 \leq \rho < 0.5$, thin edge; $0.5 \leq \rho < 0.7$, intermediate edge; $\rho \geq 0.7$, thick edge).

b, Results of DEPICT tissue enrichment analysis using GTEx data. The panel shows whether the genes overlapping DEPICT-defined loci associated with general risk tolerance are significantly overexpressed (relative to genes in random sets of loci matched by gene density) in various tissues. Tissues are grouped by organ or tissue type. The orange bars correspond to tissues with significant overexpression (FDR < 0.01). The y -axis is the significance on a $-\log_{10}$ scale. See Supplementary Note for additional details.

Table 1 |

GWAS results

GWAS	Cohorts analyzed	<i>n</i>	Mean χ^2	LD Score intercept (SE)	# lead SNPs	# loci	# cond. assoc.	SNP h^2 (SE)
General risk tolerance (disc. GWAS)	UKB; 23andMe	939,908	1.85	1.04 (0.01)	124	99	91	0.046 (0.001)
General risk tolerance (repl. GWAS)	10 indep. cohorts	35,445	1.03	1.00 (0.07)	0	0	0	--
General risk tolerance (disc. + repl.)	UKB; 23andMe; 10 indep. cohorts	975,353	1.87	1.04 (0.01)	132	107	97	0.045 (0.001)
Adventurousness	23andMe	557,923	1.98	1.05 (0.01)	167	137	126	0.098 (0.002)
Automobile speeding propensity	UKB	404,291	1.53	1.03 (0.01)	42	36	33	0.079 (0.003)
Drinks per week	UKB	414,343	1.61	1.03 (0.01)	85	62	61	0.085 (0.003)
Ever smoker	UKB; TAG Consortium ⁴⁴	518,633	1.97	1.05 (0.01)	223	183	172	0.109 (0.003)
Number of sexual partners	UKB	370,711	1.77	1.04 (0.01)	117	97	88	0.128 (0.003)
First PC of the four risky behaviors	UKB	315,894	1.77	1.05 (0.01)	106	89	84	0.156 (0.004)

The table provides an overview of the GWAS of our primary and supplementary phenotypes. Replication analysis of the lead SNPs' association results in independent cohorts was only conducted for the discovery GWAS of general risk tolerance. "*n*": GWAS sample size; "Mean χ^2 ": mean GWAS chi-squared statistics across HapMap3 SNPs with minor allele frequency (MAF) greater than 0.01; "LD Score intercept": estimate of the intercept from a LD Score regression¹¹ using HapMap3 SNPs with MAF greater than 0.01; "# lead SNPs": number of approximately independent (pairwise $r^2 < 0.1$) lead SNPs; "# loci": number of associated loci; "# cond. assoc.": number of conditional associations in the COJO analysis¹³; "SNP h^2 ": SNP heritability estimated with the Heritability Estimator from Summary Statistics (HESS) method¹⁷ using 1000 Genomes phase 3 SNPs with MAF greater than 0.05; "disc.": discovery; "repl.": replication; "indep.": independent.